Kim Straley

Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in <i>IDH2</i> - and <i>TET2</i> -Mutant Acute Myeloid Leukemia

Alan H. Shih, Cem Meydan, Kaitlyn Shank et al. · Cancer Discovery · 2017 · 112 citations

Medicine, Molecular Genetics, Oncology +17

AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo

Erica Hansen, Cyril Quivoron, Kim Straley et al. · Blood · 2014 · 48 citations

Medicine, Cancer Biology, Oncology +4

AG-221, a Small Molecule Mutant IDH2 Inhibitor, Remodels the Epigenetic State of IDH2-Mutant Cells and Induces Alterations in Self-Renewal/Differentiation in IDH2-Mutant AML Model in Vivo

Alan H. Shih, Kaitlyn Shank, Cem Meydan et al. · Blood · 2014 · 28 citations

Medicine, Cancer Biology, Molecular Biology +14

AG-221 Offers a Survival Advantage In a Primary Human IDH2 Mutant AML Xenograft Model

Katharine Yen, Fang Wang, Jeremy Travins et al. · Blood · 2013 · 26 citations

Medicine, Molecular Biology, Oncology +7

AG-221, an Oral, Selective, First-in-Class, Potent IDH2-R140Q Mutant Inhibitor, Induces Differentiation in a Xenotransplant Model

Cyril Quivoron, Muriel D. David, Kim Straley et al. · Blood · 2014 · 19 citations

Life Sciences, Molecular Biology, Pharmacology +9